Scheduled maintenance upgrade on Saturday 2nd of July 2016 from 11.30am to 3.00pm (BST)
During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.
Alzheimer's disease: which type of amyloid-preventing
drug agents to employ?
Center for Cancer Research, Nanobiology Program, Basic Science Program, SAIC-Frederick, Inc., National Cancer Institute, Frederick, USA
Departments of Bioengineering and of Mechanical and Aerospace Engineering, and Materials Science Program, University of California, San Diego, La Jolla, USA
Department of Psychiatry, David Geffen School of Medicine, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, USA
Department of Human Molecular Genetics and Biochemistry, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
Phys. Chem. Chem. Phys., 2013,15, 8868-8877
Received 02 Jan 2013, Accepted 20 Feb 2013
First published online 21 Feb 2013
This article is part of themed collection: Biophysical studies on protein misfolding and amyloid diseases
| | | | | | More